Cancer gene therapy strategies can take diverse forms, such as: (i) supplementing tumor suppression genes (e.g., p53 and mda-7/IL-14) with DNA or mRNA delivery [5,7]; (ii) silencing oncogenes with RNA interference (e.g., using siRNA) [6]; and (iii) stimulating the patients’ immune system against the disease with mRNA cancer vaccines encoding tumor antigens [8,9,10,13] or intratumoral vaccines with genes encoding immunomodulatory proteins [16]. The gene discussed is TXLNA; the disease is cancer.